File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s12928-020-00723-w
- Scopus: eid_2-s2.0-85098513895
- PMID: 33387354
- WOS: WOS:000604195300001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Factors associated with long-term major adverse cardiac events of coronary bioresorbable vascular scaffold
Title | Factors associated with long-term major adverse cardiac events of coronary bioresorbable vascular scaffold |
---|---|
Authors | |
Keywords | Percutaneous coronary intervention Bioresorbable vascular scaffold Absorb |
Issue Date | 2021 |
Publisher | Springer Japan KK. The Journal's web site is located at http://www.springer.com/medicine/cardiology/journal/12928 |
Citation | Cardiovascular Intervention and Therapeutics, 2021, v. 36, p. 462-469 How to Cite? |
Abstract | The long-term clinical outcomes after implantation of bioresorbable vascular scaffolds (BVS) in a real-world cohort were not well described. To identify factors associated with major adverse cardiovascular events (MACE) on long-term follow-up after implantation of BVS in patients undergoing elective percutaneous coronary intervention (PCI). This was an observational study based on a hospital registry of percutaneous coronary intervention. Participants were consecutive patients who underwent PCI and implanted with at least one everolimus-eluting BVS (Absorb(R)) in a single center between 2014 and 2017. Among the 170 cases analyzed (mean age 60.4 +/- 10.7), a total of 203 Absorb BVS were implanted. MACE developed in 33 (19.4%) patients over a median follow-up period of 61 months, including 9 (5.3%) deaths, 13 (7.6%) non-fatal myocardial infarction and 19 (11.2%) ischemia driven target vessel revascularization. Definite or probable stent thrombosis developed in 4 (2.4%) patients. In crude analysis, history of smoking and initial presentation of non-ST elevation-acute coronary syndrome (NSTE-ACS) were predictors of long-term MACE. In adjusted analysis, presentation with NSTE-ACS was an independent predictor of long-term MACE [adjusted odds ratio (OR) 4.52; 95% confidence interval (95% CI) 1.50 to 13.6, P = 0.007]. Among patients receiving implantation of ABSORB BVS, presentation with NSTE-ACS was an independent predictor of MACE after a median follow-up period of 61 months. Future research is needed to confirm these findings and to determine the long-term safety of BVS in patients with NSTE-ACS. |
Persistent Identifier | http://hdl.handle.net/10722/306500 |
ISSN | 2023 Impact Factor: 3.1 2023 SCImago Journal Rankings: 0.822 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ng, AKY | - |
dc.contributor.author | Ng, PY | - |
dc.contributor.author | Siu, CW | - |
dc.contributor.author | Jim, MH | - |
dc.date.accessioned | 2021-10-22T07:35:30Z | - |
dc.date.available | 2021-10-22T07:35:30Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Cardiovascular Intervention and Therapeutics, 2021, v. 36, p. 462-469 | - |
dc.identifier.issn | 1868-4300 | - |
dc.identifier.uri | http://hdl.handle.net/10722/306500 | - |
dc.description.abstract | The long-term clinical outcomes after implantation of bioresorbable vascular scaffolds (BVS) in a real-world cohort were not well described. To identify factors associated with major adverse cardiovascular events (MACE) on long-term follow-up after implantation of BVS in patients undergoing elective percutaneous coronary intervention (PCI). This was an observational study based on a hospital registry of percutaneous coronary intervention. Participants were consecutive patients who underwent PCI and implanted with at least one everolimus-eluting BVS (Absorb(R)) in a single center between 2014 and 2017. Among the 170 cases analyzed (mean age 60.4 +/- 10.7), a total of 203 Absorb BVS were implanted. MACE developed in 33 (19.4%) patients over a median follow-up period of 61 months, including 9 (5.3%) deaths, 13 (7.6%) non-fatal myocardial infarction and 19 (11.2%) ischemia driven target vessel revascularization. Definite or probable stent thrombosis developed in 4 (2.4%) patients. In crude analysis, history of smoking and initial presentation of non-ST elevation-acute coronary syndrome (NSTE-ACS) were predictors of long-term MACE. In adjusted analysis, presentation with NSTE-ACS was an independent predictor of long-term MACE [adjusted odds ratio (OR) 4.52; 95% confidence interval (95% CI) 1.50 to 13.6, P = 0.007]. Among patients receiving implantation of ABSORB BVS, presentation with NSTE-ACS was an independent predictor of MACE after a median follow-up period of 61 months. Future research is needed to confirm these findings and to determine the long-term safety of BVS in patients with NSTE-ACS. | - |
dc.language | eng | - |
dc.publisher | Springer Japan KK. The Journal's web site is located at http://www.springer.com/medicine/cardiology/journal/12928 | - |
dc.relation.ispartof | Cardiovascular Intervention and Therapeutics | - |
dc.rights | This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/[insert DOI] | - |
dc.subject | Percutaneous coronary intervention | - |
dc.subject | Bioresorbable vascular scaffold | - |
dc.subject | Absorb | - |
dc.title | Factors associated with long-term major adverse cardiac events of coronary bioresorbable vascular scaffold | - |
dc.type | Article | - |
dc.identifier.email | Ng, PY: pyeungng@hku.hk | - |
dc.identifier.email | Siu, CW: cwdsiu@hkucc.hku.hk | - |
dc.identifier.authority | Ng, PY=rp02517 | - |
dc.identifier.authority | Siu, CW=rp00534 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1007/s12928-020-00723-w | - |
dc.identifier.pmid | 33387354 | - |
dc.identifier.scopus | eid_2-s2.0-85098513895 | - |
dc.identifier.hkuros | 328528 | - |
dc.identifier.volume | 36 | - |
dc.identifier.spage | 462 | - |
dc.identifier.epage | 469 | - |
dc.identifier.isi | WOS:000604195300001 | - |
dc.publisher.place | Japan | - |